Mursla Bio Joins ABHI US Accelerator

Mursla Bio, a leader in Extracellular Vesicle (EV) science, has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator program. This initiative will provide Mursla Bio with structured access to the US market for its FDA-designated liver cancer surveillance test, EvoLiver. The program offers access to over 300 senior healthcare leaders across 35 hospitals, 20 health systems, and US insurers, along with operational guidance from entities like BD (company) and United States===Dell Medical School at the University of Texas. This is expected to accelerate EvoLiver's integration into clinical workflows and facilitate early adoption in specialist hepatology centers. Mursla Bio is actively preparing for the US launch, including CLIA lab preparation and engagement with key opinion leaders. EvoLiver is a blood test designed to improve liver cancer detection in high-risk patients, addressing limitations of current approaches and aiming to combat the rising liver cancer mortality in the United States.